Myrexis (Myrexis) 6-Month Price Index : 2.23 (As of Apr. 27, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Myrexis 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2024-04-27), Myrexis's 6-Month Price Index is 2.23.

Competitive Comparison of Myrexis's 6-Month Price Index

For the Shell Companies subindustry, Myrexis's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myrexis (OTCPK:MYRX) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index

Current Share Price

Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myrexis (OTCPK:MYRX) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Myrexis 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of Myrexis's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.

Myrexis (Myrexis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » 6-Month Price Index

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020

Website

http://www.myrexis.com

Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.

Executives

Xstelos Corp.	10 percent owner	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Steven D Scheiwe	director	1741 EDGEFIELD LANE, ENCINITAS CA 92024
Pearce Michael Cooper	director	213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Jonathan Couchman	director, officer: Chairman, President and CEO	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
John T Henderson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
First Eagle Investment Management, Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Gerald P. Belle	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
David W Gryska	director, officer: Chief Operating Officer	749 N MARY AVE, SUNNYVALE CA 94085
Richard B Brewer	director, officer: President and CEO	C/O DENDREON CORP, 3005 1ST AVE, SEATTLE WA 98121
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Dennis Langer	director	C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Robert Forrester	director	C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Adrian N Hobden	director, officer: President and CEO	320 WAKARA WAY, SALT LAKE CITY UT 84108
W Wayne Laslie	officer: Chief Operating Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108

Myrexis (Myrexis) Headlines

From GuruFocus

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-17-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-16-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-K)

By gurufocus 10qk • 09-13-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2009

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-09-2011